Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of chlorogenic acid in preparing medicament for treating marrow fibrillation

A technology for bone marrow fibrosis and chlorogenic acid, which can be used in drug combinations, pharmaceutical formulas, medical preparations containing active ingredients, etc., and can solve the problems that chlorogenic acid has not yet been discovered

Active Publication Date: 2011-09-07
SICHUAN JIUZHANG BIO TECH CO LTD
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, in the prior art, no relevant reports have been found that chlorogenic acid has an impact on bone marrow efficacy.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of chlorogenic acid in preparing medicament for treating marrow fibrillation
  • Use of chlorogenic acid in preparing medicament for treating marrow fibrillation
  • Use of chlorogenic acid in preparing medicament for treating marrow fibrillation

Examples

Experimental program
Comparison scheme
Effect test

experiment example 1

[0035] [Experimental example 1] Effect of chlorogenic acid on bone marrow suppression caused by physical factors in mice

[0036] Chlorogenic acid, with a content of 99.56%, is formulated into the required concentration with sodium chloride injection. Positive control drug: Recombinant human granulocyte colony stimulating factor injection, 300ug / tube, 1.2ml / tube.

[0037] SPF ICR mice weighing 22-30g, 240 mice. According to body weight and sex, they were randomly divided into high, medium and low-dose chlorogenic acid groups, positive control group, model control group and normal control group, with 40 animals in each group, half male and female. All animals except the normal control group are used 60 Whole body irradiation of Coγ-rays, the irradiation dose is 4Gy (dose rate is 256Gy / h, irradiation time is 2min), after irradiation, each group is given corresponding test substance according to Table 1 (control group and model group are given volume of sodium chloride injection ), ...

experiment example 2

[0094] [Experimental example 2] The effect of chlorogenic acid on bone marrow suppression caused by chemical factors in dogs

[0095] Chlorogenic acid, content 99.56%, positive control drug: Li Kejun tablets, 20 mg / tablet, three times a day (3 tablets), cyclophosphamide for injection (abbreviated as CY), white powder, 200 mg / ampoule, 5 bottles / Boxed. 36 Beagle dogs (male and female), normal, healthy, uniform in weight, female not pregnant, weighing 6-7kg, and age 6 months.

[0096] The dosage design is shown in Table 19.

[0097] Table 19 Dose Design

[0098]

[0099] In addition to the normal control group, dogs in the other 5 groups were intravenously injected with 8 mg / ml cyclophosphamide 0.8 ml / kg (8 mg / kg) once a day for 5 consecutive days. On the 6th day, each test drug was given according to Table 19. The model control group and the normal control group were given normal saline for 13 consecutive days. Before modeling, every day after modeling, and 2, 4, 6, 8, 10, 12, and 1...

experiment example 3

[0127] [Experimental example 3] Chlorogenic acid pair 60 Protective effects of Co-γ rays on the damage of hematopoietic stem cells in spleen of mice

[0128] 1. Experimental method

[0129] Take Health C 57 60 mice were randomly divided into 5 groups according to gender and body weight. The rats in the negative group were given intraperitoneal injection of 0.4ml / 20g body weight with normal saline, and the mice in the positive group (granulocyte colony stimulating factor) were given intraperitoneal injection of 0.4ml / 20g body weight (2ug / kg). 0.1%, 0.05% and 0.025% of chlorogenic acid liquid was injected intraperitoneally with 0.4ml / 20g body weight (dose 20, 10 and 5mg / kg) to each mouse in each group. The rats in the above 5 groups were administered once a day for 7 consecutive days. On the 7th day, the surviving animals were weighed, 1 hour after the last administration. The mice in each group were sacrificed by cervical dislocation on the 9th day after whole body irradiation. Th...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a use of chlorogenic acid in preparing medicament for treating marrow fibrillation and also provides a pharmaceutical composition containing the chlorogenic acid as the active constituent.

Description

[0001] This application is a divisional application with application number: 200680024175.X (PCT / CN2006 / 001795). Original application application number: 200680024175.X (PCT / CN2006 / 001795), application date: July 21, 2006, title of invention: use of chlorogenic acid in the preparation of medicines with the effect of increasing bone marrow cells. Technical field [0002] The present invention relates to a new use of chlorogenic acid, specifically, the use of chlorogenic acid in the preparation of medicines for treating myelofibrosis. Background technique [0003] Chlorogenic acid is widely present in various medicinal plants such as honeysuckle, and its chemical structure has been clearly studied at present. Some people have conducted medicinal studies on it and reported that chlorogenic acid can be used to treat tumors and other diseases. [0004] Chlorogenic acid is a kind of phenols isolated from the leaves and fruits of dicotyledonous plants (such as honeysuckle leaves, coffee be...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/216A61P43/00
Inventor 张洁张舒张亮徐小平包旭易大朝
Owner SICHUAN JIUZHANG BIO TECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com